Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

MRSN

Mersana Therapeutics (MRSN)

Mersana Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MRSN
DateHeureSourceTitreSymboleSociété
12/06/202423h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MRSNMersana Therapeutics Inc
11/06/202422h25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MRSNMersana Therapeutics Inc
22/05/202414h00GlobeNewswire Inc.Mersana Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:MRSNMersana Therapeutics Inc
17/05/202414h26Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:MRSNMersana Therapeutics Inc
10/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MRSNMersana Therapeutics Inc
09/05/202423h06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MRSNMersana Therapeutics Inc
09/05/202415h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MRSNMersana Therapeutics Inc
09/05/202412h59GlobeNewswire Inc.Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial ResultsNASDAQ:MRSNMersana Therapeutics Inc
03/05/202422h30GlobeNewswire Inc.Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MRSNMersana Therapeutics Inc
02/05/202414h00GlobeNewswire Inc.Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024NASDAQ:MRSNMersana Therapeutics Inc
28/02/202422h05Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:MRSNMersana Therapeutics Inc
28/02/202414h49Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MRSNMersana Therapeutics Inc
28/02/202414h43Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:MRSNMersana Therapeutics Inc
28/02/202413h00GlobeNewswire Inc.Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:MRSNMersana Therapeutics Inc
21/02/202414h00GlobeNewswire Inc.Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024NASDAQ:MRSNMersana Therapeutics Inc
16/02/202422h30Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:MRSNMersana Therapeutics Inc
15/02/202402h56Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MRSNMersana Therapeutics Inc
01/02/202414h00GlobeNewswire Inc.Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology ConferenceNASDAQ:MRSNMersana Therapeutics Inc
17/01/202403h14Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MRSNMersana Therapeutics Inc
12/01/202422h42Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:MRSNMersana Therapeutics Inc
05/01/202414h01GlobeNewswire Inc.Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:MRSNMersana Therapeutics Inc
07/11/202313h00GlobeNewswire Inc.Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial ResultsNASDAQ:MRSNMersana Therapeutics Inc
31/10/202321h30GlobeNewswire Inc.Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023NASDAQ:MRSNMersana Therapeutics Inc
31/10/202317h59Dow Jones NewsMersana Therapeutics Shares Rise 8% After FDA Lifts Clinical Hold for Cancer TreatmentNASDAQ:MRSNMersana Therapeutics Inc
31/10/202314h07Dow Jones NewsMersana Says FDA Lifts Clinical Hold on Gastric-Cancer Treatment Phase I TrialNASDAQ:MRSNMersana Therapeutics Inc
31/10/202313h00GlobeNewswire Inc.Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056NASDAQ:MRSNMersana Therapeutics Inc
07/09/202323h46Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MRSNMersana Therapeutics Inc
06/09/202313h00GlobeNewswire Inc.Mersana Therapeutics Announces Changes in LeadershipNASDAQ:MRSNMersana Therapeutics Inc
08/08/202314h00GlobeNewswire Inc.Mersana Therapeutics Announces Second Quarter 2023 Financial ResultsNASDAQ:MRSNMersana Therapeutics Inc
27/07/202313h06GlobeNewswire Inc.Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic ReprioritizationNASDAQ:MRSNMersana Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:MRSN

Dernières Valeurs Consultées

Delayed Upgrade Clock